Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
988 Views
eMediNexus 30 June 2018
In a study published June 28, 2018 in the NEJM, patients with uncontrolled asthma who received dupilumab had significantly lower rates of severe asthma exacerbation vs those who received placebo. They also had better lung function and asthma control. Greater benefits were seen in patients with higher baseline levels of eosinophils.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}